Development of New Diagnostic Method for Lymph Nodes Using 5-Aminolevulinic Acid in Uterine endometrial Patients.

Development of New Diagnostic Method for Lymph Nodes Using 5-Aminolevulinic Acid in Uterine endometrial Patients. - Development of New Diagnostic Method for Lymph Nodes Using 5-Aminolevulinic Acid in Uterine endometrial Patients.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023436

Enrollment

Registered

2016-10-01

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine endometrial cancer

Interventions

5-aminolevulinic acid

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Age older than 20 years 2 .Diagnosed with operable endometrial cancer 3. Informed consent is signed

Exclusion criteria

Exclusion criteria: 1. Porphyria 2. With history of hypersensitivity reaction for 5-aminolevulinic acid or porphyrin 3. For whom drugs that can cause photosensitivity disease is needed 4. Apparently or possibly pregnant or have desire to be come pregnant 5. Cases who physician judged improper to entry this trial

Design outcomes

Primary

Measure	Time frame
To confirm the safety of 5-ALA and the performance of the measuring instrument. To check the matching rate between 5-ALA method and rapid or permanent pathological diagnosis.	—

Countries

Japan

Contacts

Public ContactTaisuke Mori

Kyoto Prefectural University of Medicine Obstetrics and Gynecology

aoi@koto.kpu-m.ac.jp+81-75-251-5560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026